Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 13/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1727740 | 0.88 | CKS1B (0.47) | CHRM4PDE10AAKR1C3PPARGPPARD | |
| SCHEMBL1728839 | 0.86 | CHRM4 (0.52) | CHRM4CHRM1CHRM2PDE10ACHRM5 | |
| SCHEMBL1728730 | 0.85 | MAOA (0.55) | CHRM4CHRM1CHRM2PDE10ACHRM5 | |
| SCHEMBL346471 | 0.84 | CHRM4 (0.52) | CHRM4CHRM1CHRM2PPARGPPARD | |
| SCHEMBL16174444 | 0.83 | CHRM4 (0.47) | CHRM4CHRM1CHRM2PDE10AAKR1C3 | |
| SCHEMBL16174446 | 0.83 | CHRM4 (0.47) | CHRM4CHRM1CHRM2PDE10AAKR1C3 | |
| SCHEMBL1730242 | 0.83 | CHRM4 (0.68) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL3269077 | 0.82 | CHRM4 (0.49) | CHRM4CHRM1CHRM2PDE10AAKR1C3 | |
| SCHEMBL1711018 | 0.81 | CHRM4 (0.57) | CHRM4CHRM1CHRM2 | |
| SCHEMBL1728738 | 0.81 | CHRM4 (0.50) | CHRM4CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912218-B2 | Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-12-16 | — | — | US | disclosed |
| EP-2356108-B1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-10-15 | — | — | EP | disclosed |
| US-8716289-B2 | Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| EP-2344486-B1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THEIR USE AS FAAH INHIBITORS | SANOFI SA (FR) | 2013-03-27 | — | — | EP | disclosed |
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-09-01 | — | — | US | disclosed |
| EP-2356108-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-08-17 | — | — | EP | disclosed |
| EP-2344486-A2 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010055267-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010010288-A2 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MET, ALK, REL | CHRM4 1891/4885CHRM1 1460/4885CHRM2 2124/4885 |
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | CHRM4 1210/4885CHRM1 308/4885CHRM2 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.